Trials / Completed
CompletedNCT01456546
Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- University of Southern Denmark · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate if the genetic variant CYP2C19\*17 affects the pharmacokinetics of proguanil and clopidogrel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Proguanil | 2x350 mg Malarone followed by 3 days of blood- and urine sampling |
| DRUG | Clopidogrel | 2x300 mg Plavix followed by 7 hours days of blood sampling |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2011-10-20
- Last updated
- 2013-07-03
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01456546. Inclusion in this directory is not an endorsement.